Clinical trials: Epithelial Mesothelioma
Mesothelioma, Pleural Mesothelioma
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.
- Conditions
- Mesothelioma, Pleural Mesothelioma, Wilms Tumor
- Trial name
- NCT04040231
- Testing
- Galinpepimut-S, Nivolumab, Sargramostim
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mesothelioma, Homologous Recombination Deficiency
Olaparib in Patients With HRD Malignant Mesothelioma
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations).
- Trial name
- NCT04515836
- Testing
- Olaparib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Chicago
Thymus Tumors, Adoptive Cellular Therapy
Rapid Autopsy and Procurement of Cancer Tissue
Background: Individuals with cancer of the lung, chest cavity, ovary, or bladder, as well as patients who have been treated with adoptive cell therapy unfortunately commonly succumb to their disease.
- Conditions
- Thymus Tumors, Adoptive Cellular Therapy, Mesothelioma, Genitourinary Cancers
- Trial name
- NCT01851395
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma
Short Neoadjuvant Hemithoracic IMRT for MPM
Malignant pleural mesotheliomas (MPMs) are tumours associated with asbestos exposure involving the tissue lining surrounding the lung.
- Trial name
- NCT00797719
- Testing
- Pre-op RT +/- chemotherapy
- Where
- Canada
- Volunteers
- 104 people
- Sponsor
- University Health Network, Toronto
Malignant Pleural Mesotheliomas
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma.
- Trial name
- DUAL-MESO-NK (NCT07510815)
- Testing
- EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-II
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-II (NCT03655821)
- Testing
- Pemetrexed
- Where
- 5 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Radboud University Medical Center
Malignant Pleural Mesothelioma
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
- Trial name
- PENINSULA (NCT06318286)
- Testing
- Lenvatinib, Pemetrexed, Cisplatin/Carboplatin
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Hyogo Medical University
Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell
Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide. In Egypt, lung carcinoma ranks the 5th among all cancer cases.
- Conditions
- Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell, Mesothelioma; Lung
- Trial name
- NCT05228795
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Pleural Malignant Mesothelioma
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
This phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine works in treating patients with mesothelin-positive pleural mesothelioma.
- Trial name
- NCT03126630
- Testing
- Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 33 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma, Non Small Cell Lung Cancer
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the…
- Conditions
- Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
- Trial name
- NCT05245500
- Testing
- MRTX1719
- Where
- 25 sites in United States
- Volunteers
- 336 people
- Sponsor
- Bristol-Myers Squibb
Malignant Pleural Mesothelioma
Response Evaluation in Malignant Pleural Mesothelioma
Recently, a few small trials have shown promising results on value of fluoro-2-deoxy-D-glucose and positron emission tomography imaging in response assessment in Malignant Pleural Mesothelioma.
- Trial name
- NCT00969098
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Istituto Clinico Humanitas
Malignant Mesothelioma
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant…
- Trial name
- NCT00770120
- Testing
- everolimus
- Where
- 129 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Malignant (Pleural) Mesothelioma
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
Earlier the investigators determined the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in mesothelioma patients.
- Trial name
- PMR-MM-002 (NCT01241682)
- Testing
- DC + CTX
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Erasmus Medical Center
Mesothelioma
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
- Trial name
- NCT03683680
- Testing
- MPT Test, CLDN15/VIM Test
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer
A Study in Non Small Cell Lung Cancer
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer.
- Trial name
- NCT01139775
- Testing
- Pemetrexed, Cisplatin, LY2603618
- Where
- 24 sites in Germany, Spain
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Malignant Pleural Mesothelioma
Autologous Dendritic Cell Vaccination in Mesothelioma
In this multicenter phase I/II trial, dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be used in conjunction with conventional chemotherapy for the frontline treatment of malignant pleural…
- Trial name
- MESODEC (NCT02649829)
- Testing
- dendritic cell vaccination plus chemotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 28 people
- Sponsor
- University Hospital, Antwerp
Carcinoma, Pancreatic Ductal, Mesothelioma
Amatuximab for High Mesothelin Cancers
Background: Amatuximab is a cancer treatment drug that targets mesothelin. High levels of this substance are found on some kinds of tumor cells.
- Conditions
- Carcinoma, Pancreatic Ductal, Mesothelioma, Ovarian Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01413451
- Testing
- Amatuximab (MORab-009)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00243074
- Testing
- cediranib maleate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Mesothelioma
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Combining photodynamic therapy with surgery may be an effective treatment for malignant mesothelioma.
- Trial name
- NCT00054002
- Testing
- adjuvant therapy, conventional surgery, porfimer sodium
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Roswell Park Cancer Institute
Stomach Neoplasms, Colorectal Neoplasms
Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
OBJECTIVES: Determine response and survival of patients with peritoneal carcinomatosis treated with cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin Assess the quality of…
- Conditions
- Stomach Neoplasms, Colorectal Neoplasms, Neoplasm Metastasis, Mesothelioma
- Trial name
- IPHC (NCT00454519)
- Testing
- cytoreductive surgery, intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wuhan University